

AD

STUDENT LOAN REFI + CHECKING

Rates as low as 1.37% Variable APR with discounts
when you open a checking account during student loan refinancing.



FOR DOCTORS

LEARN MORE

Laurel Road is a brand of KeyBank N.A. Member FDIC

Journal of Clinical Oncology®

An American Society of Clinical Oncology Journal

Log In



Submit



E-Alerts



Cart

[OpenAthens/Shibboleth »](#)

MENU

[Journal of Clinical Oncology](#) > [List of Issues](#) >
[Volume 39, Issue 15 suppl](#) >

Meeting Abstract | 2021 ASCO Annual Meeting I



Article Tools

MELANOMA/SKIN CANCERS

The influence of harvest method on dendritic cell function and clinical outcomes in a randomized trial of a dendritic cell vaccine to prevent recurrences in high-risk melanoma.



Check for updates

[Alexandra Adams](#), [G. Travis Clifton](#), [Timothy J. Vreeland](#),
[Anne E. O'Shea](#), [Patrick M. McCarthy](#), [Robert Connor Chick](#),

OPTIONS & TOOLS

[Export Citation](#)[Track Citation](#)[Add To Favorites](#)[Rights & Permissions](#)

COMPANION ARTICLES

No companion articles

ARTICLE CITATION

ADVERTISEMENT

Laurel R
PhysiciaRATE
ON TILock in y
and start

Learn I



FOR DOCTORS

Laurel Road is a bran
#399791

This site uses tracking technologies through the use of permanent cookies and web beacons/pixel tags. By default, cookies are set to "Allow all cookies." If you continue to use this site, then you acknowledge our use of cookies. For additional information, including on how to change your cookie settings, please visit "Cookies Settings" and review our [Privacy Policy](#) and [Terms of Use](#).

[Cookie Settings](#)
[Accept Cookies](#)


Background: A randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle loaded, dendritic cell (TLPLDC) vaccine was conducted to prevent recurrence in patients (pts) with resected stage III/IV melanoma. Two methods for dendritic cell (DC) harvest were used for vaccine production, including no pretreatment or pretreatment with granulocyte-colony stimulating factor (G-CSF) in an attempt to reduce blood draw volumes. This analysis investigates differences in clinical outcomes and RNA gene expression between these DC harvest methods for TLPLDC vaccine creation. **Methods:** The TLPLDC vaccine is created by loading autologous tumor lysate into yeast cell wall particles (YCWP) and exposing them to phagocytosis by DCs. By investigator/pt choice, pts had 120mL of blood drawn for DC harvest, or pts received 300µg of G-CSF for pre-DC mobilization and a 50-70 mL blood draw 24-48 hours later. Total vaccine production time was 72 hrs. Pts were randomized 2:1 to receive TLPLDC or placebo (DCs exposed to empty YCWPs). 1-1.5 x10⁶ cells/dose were injected intradermally at 0, 1, 2, 6, 12, and 18 months. Differences in disease free survival (DFS) and overall survival (OS) were evaluated by Kaplan Meier analysis between pts who did not receive pretreatment (TLPLDC), pts who did receive pretreatment with G-CSF (TLPLDC+G), and pts receiving placebo. RNA-seq analysis was performed on the total RNA of pts' prepared TLPLDC vaccines to assess gene expression. Relative RNA expression (RRE) was compared between TLPLDC and TLPLDC+G. **Results:** As previously reported, 144 pts were randomized:

102 received TLPLDC (46 TLPLDC, 57 TLPLDC+G, 43 placebo)

This site uses tracking technologies through the use of permanent cookies and web beacons/pixel tags. By default, cookies are set to "Allow all cookies." If you continue to use this site, then you acknowledge our use of cookies. For additional information, including on how to change your cookie settings, please visit "Cookies Settings" and review our [Privacy Policy](#) and [Terms of Use](#).

WE RECOMMEND


Arming the Immune System Through Vaccination to Prevent Cancer Recurrence
Diane F. Hale et al., ASCO Ed Book, 2016


Impact of chemotherapy (CT) on ex-vivo generation of dendritic cells (DCs) in advanced breast cancer (ABC) patients (pts)
S. Ferrari et al., J Clin Oncol, 2004

Getting Melanoma Cells to Stimulate With Frequency
William E. Carson, J Clin Oncol, 2016

Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells
Craig L. Slingluff Jr et al., J Clin Oncol, 2016

Phase III Trial Shows No Benefit of Adjuvant GM-CSF or Peptide Vaccine in High-Risk, Resected Melanoma
By Matthew Stenger, The ASCO Post, 2015

Where Do Current Vascular Access Guidelines Land on Risk Mitigation? 
ReachMD

Advanced clinical trials of dendritic cell vaccines in ovarian cancer 
Quan Guo et al., Journal of Investigative Medicine, 2020

ADVERTISEMENT

Laurel Road
Physician Mortgage

**\$0
DOWN +
NO PMI**

[Learn More](#)

Conditions and restrictions may apply.

 **FOR DOCTORS** Laurel Road is a brand #399791

ASCO Career C

Bread-n-Butter Hem/Onc Pract Southern Maryland

Maryland (US) | up to \$600K

We are looking for a community focused Hem/Onc to join a large, integrated system in Coastal Maryland, located miles from DC! This i...

Employer: Pacific Companies [Apply](#)

Breast Oncologist

Burlington, Vermont | Upon Discussi

DIVISION OF HEMATOLOGY/ONC
DEPARTMENT OF MEDICINE UNI
OF VERMONT CANCER CENTER,
COLLEGE OF MEDICINE The Divis
Hematology/...

Employer: University of Vermont Medical C
[Apply](#)

BMT Physician - OHC Cincinnati

Cincinnati, OH | Comprehensive

[Overview OHC \(Oncology Hematol](#)

ADVERTISEMENT

**ASCO's Equity,
Diversity,
and Inclusion
Action Plan**
Read more at
asco.org/equity

[Cookie Settings](#)

[Accept Cookies](#)



vs 27.1%, $p = 0.027$). When compared to TLPLDC+G ($n = 3$) vaccine, RNA-seq from TLPLDC vaccine ($n = 3$) showed upregulation of genes associated with DC maturation, including HLA-DMB (RRE: 3.60), IFIT1 (3.38), CD27 (3.26), IFI44L (3.24), MX1 (2.96), HLA-DQA1 (2.67), HLA-DRA (2.40), CD49D (2.34) and CD74 (2.09), while downregulated genes were associated with DC suppression or immaturity including SERPINA1 (RRE:7.8), TLR2 (6.65), CCR1 (5.11), IL10 (4.19), CD93 (3.84) and CD14 (3.25). **Conclusions:** Pts receiving TLPLDC vaccine had significantly improved OS and DFS, while outcomes remained similar between those who received TLPLDC+G vs placebo. Pts who did not receive G-CSF had higher expression of genes linked to DC maturation and antigen processing and presentation, likely explaining the improvement in clinical efficacy. A phase III trial to further assess the TLPLDC vaccine to prevent recurrence is planned. [Clinical trial information: NCT02301611](#).²

© 2021 by American Society of Clinical Oncology

Patrick McCarthy et al., Jitc, 2020

Adjuvant GM-CSF, peptide vaccination fail to improve survival for advanced melanoma ²

Healio

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma ²

Chantal Saberian et al., Jitc, 2021

Powered by
TREND MD



Research Sponsor:

Elios Therapeutics



QUICK LINKS

Content

Newest Articles

Archive

Meeting Abstracts

Journal Information



ASCO FAMILY OF SITES

Journals

Journal of Clinical

Oncology

JCO Oncology Practice

JCO Global Oncology

JCO Clinical Cancer

This site uses tracking technologies through the use of permanent cookies and web beacons/pixel tags. By default, cookies are set to "Allow all cookies." If you continue to use this site, then you acknowledge our use of cookies. For additional information, including on how to change your cookie settings, please visit "Cookies Settings" and review our [Privacy Policy](#)² and [Terms of Use](#)².

› [Cookie Settings](#)

✓ [Accept Cookies](#)



[Institutions](#)[Advertisers](#)[Submit Your
Manuscript](#)[Subscribe to this
Journal](#)

Education

[ASCO eLearning](#)[ASCO Meetings](#)[Cancer.Net](#)

Other Sites

[ASCO.org](#)[ASCO Author Services](#)[ASCO Career Center](#)[CancerLinQ](#)[Conquer Cancer](#)[Foundation](#)[TAPUR Study](#)[American Society of Clinical Oncology](#)

2318 Mill Road, Suite 800, Alexandria, VA 22314

© 2022 American Society of Clinical Oncology

[Terms of Use](#) | [Privacy Policy](#) | [Cookies](#)

This site uses tracking technologies through the use of permanent cookies and web beacons/pixel tags. By default, cookies are set to “Allow all cookies.” If you continue to use this site, then you acknowledge our use of cookies. For additional information, including on how to change your cookie settings, please visit “Cookies Settings” and review our [Privacy Policy](#) and [Terms of Use](#).

[Cookie Settings](#)[✓ Accept Cookies](#)